Graminae pollen allergen mutants for specific immunotherapy, and production and use of the same

US6919086B1 · kind B1 · utility

Assignee

• Merck Patentgesellschaft · DE

Inventors

• Helga Kahlert · Hamburg, DE
• Hans-Thomas Stüwe · Darmstadt, DE
• Helmut Fiebig · Schwarzenbek, DE
• Oliver Cromwell · Bad Nenndorf, DE
• Wolf-Meinhard Becker · Darmstadt, DE
• Albrecht Bufe · Darmstadt, DE
• Gabriele Schramm · Ellrich, DE
• Lothar Jäger · Darmstadt, DE
• Wolf-Dieter Müller · Darmstadt, DE

Key dates

• Filing date: Mar 16, 1998
• Grant date: Jul 19, 2005
• Expiry date: Mar 16, 2018

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to modified recombinant allergen mutants which can be obtained from recombinant allergens which are derived from allergens which can be obtained by extraction from natural raw materials such as pollen of the species Phleum pratense. While these modified recombinant allergens stimulate lymphocytes from patients who are allergic to pollent to proliferate and synthesize cytokines, they exhibit a markedly diminished ability to bind to the IgE antibodies which are present in the serum of the T lymphocyte donors and to grass pollen allergen-specific IgEs and can therefore be used for a specific, made-to-release allergy therapy.